joseph ciccolini
joseph ciccolini
Aix Marseille Univ (AMU, SMARTc COMPO CRCM) and Assistance Publique Hôpitaux de Marseille (APHM)
Verified email at - Homepage
Cited by
Cited by
Clinical pharmacokinetics and pharmacodynamics of immune checkpoint inhibitors
M Centanni, DJAR Moes, IF Trocóniz, J Ciccolini, JGC van Hasselt
Clinical pharmacokinetics 58, 835-857, 2019
Propranolol potentiates the anti-angiogenic effects and anti-tumor efficacy of chemotherapy agents: implication in breast cancer treatment
E Pasquier, J Ciccolini, M Carre, S Giacometti, R Fanciullino, C Pouchy, ...
Oncotarget 2 (10), 797, 2011
Computational oncology—mathematical modelling of drug regimens for precision medicine
D Barbolosi, J Ciccolini, B Lacarelle, F Barlési, N André
Nature reviews Clinical oncology 13 (4), 242-254, 2016
Pharmacokinetics and pharmacogenetics of Gemcitabine as a mainstay in adult and pediatric oncology: an EORTC-PAMM perspective
J Ciccolini, C Serdjebi, GJ Peters, E Giovannetti
Cancer chemotherapy and pharmacology 78, 1-12, 2016
Mathematical modeling of cancer immunotherapy and its synergy with radiotherapy
R Serre, S Benzekry, L Padovani, C Meille, N André, J Ciccolini, F Barlesi, ...
Cancer research 76 (17), 4931-4940, 2016
Pharmacogenetics of capecitabine in advanced breast cancer patients
R Largillier, MC Etienne-Grimaldi, JL Formento, J Ciccolini, JF Nebbia, ...
Clinical cancer research 12 (18), 5496-5502, 2006
Cytidine deaminase residual activity in serum is a predictive marker of early severe toxicities in adults after gemcitabine-based chemotherapies
J Ciccolini, L Dahan, N André, A Evrard, M Duluc, A Blesius, C Yang, ...
Journal of clinical oncology 28 (1), 160-165, 2010
Increased cytotoxicity and bystander effect of 5-fluorouracil and 5′-deoxy-5-fluorouridine in human colorectal cancer cells transfected with thymidine phosphorylase
A Evrard, P Cuq, J Ciccolini, L Vian, JP Cano
British journal of cancer 80 (11), 1726-1733, 1999
Mathematical modeling of tumor growth and metastatic spreading: validation in tumor-bearing mice
N Hartung, S Mollard, D Barbolosi, A Benabdallah, G Chapuisat, G Henry, ...
Cancer research 74 (22), 6397-6407, 2014
Population modeling of tumor growth curves and the reduced Gompertz model improve prediction of the age of experimental tumors
C Vaghi, A Rodallec, R Fanciullino, J Ciccolini, JP Mochel, M Mastri, ...
PLoS computational biology 16 (2), e1007178, 2020
Optimization of trans-Resveratrol bioavailability for human therapy
MJ Amiot, B Romier, TMA Dao, R Fanciullino, J Ciccolini, R Burcelin, ...
Biochimie 95 (6), 1233-1238, 2013
Optimizing druggability through liposomal formulations: new approaches to an old concept
D Bitounis, R Fanciullino, A Iliadis, J Ciccolini
International Scholarly Research Notices 2012 (1), 738432, 2012
Challenges, expectations and limits for nanoparticles-based therapeutics in cancer: a focus on nano-albumin-bound drugs
R Fanciullino, J Ciccolini, G Milano
Critical reviews in oncology/hematology 88 (3), 504-513, 2013
A rapid and inexpensive method for anticipating severe toxicity to fluorouracil and fluorouracil-based chemotherapy
J Ciccolini, C Mercier, A Evrard, L Dahan, JC Boyer, F Duffaud, K Richard, ...
Therapeutic drug monitoring 28 (5), 678-685, 2006
Routine dihydropyrimidine dehydrogenase testing for anticipating 5-fluorouracil–related severe toxicities: hype or hope?
J Ciccolini, E Gross, L Dahan, B Lacarelle, C Mercier
Clinical colorectal cancer 9 (4), 224-228, 2010
Liposome-encapsulated anticancer drugs: still waiting for the magic bullet?
R Fanciullino, J Ciccolini
Current medicinal chemistry 16 (33), 4361-4373, 2009
A simple and rapid high‐performance liquid chromatographic (HPLC) method for 5‐fluorouracil (5‐FU) assay in plasma and possible detection of patients with impaired …
J Ciccolini, C Mercier, MF Blachon, R Favre, A Durand, B Lacarelle
Journal of clinical pharmacy and therapeutics 29 (4), 307-315, 2004
Antiproliferative effect of ascorbic acid is associated with the inhibition of genes necessary to cell cycle progression
S Belin, F Kaya, G Duisit, S Giacometti, J Ciccolini, M Fontés
PloS one 4 (2), e4409, 2009
DPD-based adaptive dosing of 5-FU in patients with head and neck cancer: impact on treatment efficacy and toxicity
CG Yang, J Ciccolini, A Blesius, L Dahan, D Bagarry-Liegey, C Brunet, ...
Cancer chemotherapy and pharmacology 67, 49-56, 2011
Molecular mechanisms underlying the interaction between ZD1839 (‘Iressa’) and cisplatin/5-fluorouracil
N Magne, JL Fischel, C Tiffon, P Formento, A Dubreuil, N Renee, ...
British journal of cancer 89 (3), 585-592, 2003
The system can't perform the operation now. Try again later.
Articles 1–20